Natixis’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14,010
| Closed | -$2.19M | – | 1158 |
|
|
2025
Q3 | $2.19M | Buy |
14,010
+7,058
| +102% | +$1.12M | 0.01% | 553 |
|
|
2025
Q2 | $1.05M | Buy |
6,952
+3,980
| +134% | +$531K | ﹤0.01% | 597 |
|
|
2025
Q1 | $444K | Buy |
+2,972
| New | +$498K | ﹤0.01% | 672 |
|
|
2024
Q4 | – | Sell |
-3,473
| Closed | -$684K | – | 1068 |
|
|
2024
Q3 | $684K | Sell |
3,473
-268
| -7% | -$55.7K | ﹤0.01% | 586 |
|
|
2024
Q2 | $773K | Sell |
3,741
-164
| -4% | -$37.2K | ﹤0.01% | 543 |
|
|
2024
Q1 | $1.06M | Buy |
+3,905
| New | +$933K | 0.01% | 520 |
|
|
2023
Q2 | – | Sell |
-4,722
| Closed | -$953K | – | 1041 |
|
|
2023
Q1 | $953K | Buy |
+4,722
| New | +$1.07M | 0.01% | 532 |
|
|
2022
Q4 | – | Sell |
-30,625
| Closed | -$6.03M | – | 1138 |
|
|
2022
Q3 | $6.03M | Buy |
30,625
+27,800
| +984% | +$6M | 0.03% | 370 |
|
|
2022
Q2 | $605K | Sell |
2,825
-42,789
| -94% | -$10.5M | ﹤0.01% | 912 |
|
|
2022
Q1 | $13M | Buy |
45,614
+30,439
| +201% | +$9.39M | 0.05% | 357 |
|
|
2021
Q4 | $5.72M | Buy |
15,175
+2,562
| +20% | +$995K | 0.02% | 522 |
|
|
2021
Q3 | $5.21M | Buy |
12,613
+6,633
| +111% | +$2.75M | 0.02% | 525 |
|
|
2021
Q2 | $2.21M | Buy |
+5,980
| New | +$2M | 0.01% | 508 |
|
|
2020
Q2 | – | Sell |
-66,200
| Closed | -$8.36M | – | 751 |
|
|
2020
Q1 | $8.36M | Sell |
66,200
-6,214
| -9% | -$932K | 0.07% | 211 |
|
|
2019
Q4 | $11M | Sell |
72,414
-35,450
| -33% | -$4.91M | 0.07% | 267 |
|
|
2019
Q3 | $14.3M | Buy |
107,864
+69,281
| +180% | +$9.29M | 0.09% | 200 |
|
|
2019
Q2 | $5.47M | Sell |
38,583
-105,076
| -73% | -$14.3M | 0.04% | 310 |
|
|
2019
Q1 | $20.6M | Buy |
143,659
+92,692
| +182% | +$12.2M | 0.13% | 164 |
|
|
2018
Q4 | $5.77M | Sell |
50,967
-34,721
| -41% | -$4.35M | 0.05% | 300 |
|
|
2018
Q3 | $11.5M | Buy |
85,688
+42,666
| +99% | +$5.27M | 0.07% | 257 |
|
|
2018
Q2 | $4.83M | Buy |
+43,022
| New | +$4.65M | 0.03% | 387 |
|
|
2017
Q4 | – | Sell |
-3,132
| Closed | -$338K | – | 901 |
|
|
2017
Q3 | $338K | Sell |
3,132
-46
| -1% | -$4.73K | ﹤0.01% | 849 |
|
|
2017
Q2 | $321K | Buy |
3,178
+95
| +3% | +$8.74K | ﹤0.01% | 624 |
|
|
2017
Q1 | $277K | Buy |
+3,083
| New | +$262K | ﹤0.01% | 742 |
|
Other funds holding CRL
AI
Natixis's CRL Position: Q4 2025 in Review
Natixis sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 14,010 shares — an estimated $2.19M sold.
Natixis first reported a position in CRL in Q1 2017 and held it in 24 quarters. The position peaked at $20.6M in Q1 2019. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.
- Natixis reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
- Natixis sold 14,010 Charles River Laboratories shares in Q4 2025, an estimated $2.19M.
- Natixis first reported a position in Charles River Laboratories in Q1 2017 and held it in 24 quarters.
- Natixis's Charles River Laboratories position peaked at $20.6M in Q1 2019.
- 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.
Based on Natixis's 13F filing for Q4 2025, filed 13 Feb 2026.